Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Follow-Up Questions
¿Quién es el CEO de Vivos Inc?
Dr. Michael Korenko es el President de Vivos Inc, se unió a la empresa desde 2009.
¿Qué tal es el rendimiento del precio de la acción RDGL?
El precio actual de RDGL es de $0.0934, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Vivos Inc?
Vivos Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Vivos Inc?
La capitalización bursátil actual de Vivos Inc es $42.3M
